{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG000","lowerLimit":"7.6","upperLimit":"NA","value":"22.2"}]}],"title":"Up to approx. 3.2 years"},{"categories":[{"measurements":[{"comment":"Not estimable (NA) due to the insufficient number of participants with events","groupId":"OG000","lowerLimit":"9.2","upperLimit":"NA","value":"27.4"}]}],"title":"Up to approx. 4.8 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Time from first documented response (PR or CR) until disease progression or death as per central independent assessment using RANO criteria. CIs were estimated using the Brookmeyer Crowley method. Patients who had not progressed or died or had received further anticancer therapy were censored at the date of the last adequate tumor evaluation.\n\nCR: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks; no new lesions; and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be off steroids or only on physiologic replacement doses.\n\nPR: ≥ 50% reduction, compared to baseline, in the sum of products of the perpendicular diameters for all measurable lesions for at least 4 weeks, no progression of nonmeasureable disease, no new lesions, and stable or improved nonenhancing (T2/FLAIR) lesions. Patient must be on a corticosteroid dose not greater than the dose at the time of baseline scan and be stable or improving clinically.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the HGG cohort received dabrafenib (orally, twice daily and dosed based on weight and age) and trametinib (orally, once daily in combination with the first daily dose of dabrafenib and dosed based on weight)","id":"OG000","title":"HGG Cohort: Dabrafenib and Trametinib"}],"paramType":"MEDIAN","populationDescription":"Participants on the HGG cohort to whom study treatment had been assigned and who received at least one dose of study treatment with a confirmed CR or PR as per central independent assessment using RANO criteria","reportingStatus":"POSTED","timeFrame":"Up to approx. 3.2 years and up to approx. 4.8 years","title":"HGG Cohort: Kaplan-Meier Estimates of Duration of Response (DOR) as Per Central Independent Assessment Using RANO Criteria","type":"SECONDARY","unitOfMeasure":"Months"}